Drugs / LiveSpo Navax Kid
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06148194 | Jan → May 2024 | respiratory tract infectious disorder | Anabio R&D | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LiveSpo Navax Kid | “LiveSpo Navax Kid is prepared in the form of NaCl 0.9% plus B. subtilis and B. clausii at 0.6 billion CFU/mL x 30 mL.” NCT06148194 ↗ |
| Route | Intranasal | “direct nasal spraying of probiotics” NCT06148194 ↗ |